Pancreas Cancer

Oncology·MeSH: Pancreatic Neoplasms

Prevalence

7.1 / 100K

Incidence

7.5 / 100K/yr

6 drugs in development·3 companies·13 clinical trials

Drug Pipeline by Phase

Phase 2(1)

Drug	Company
certepetide	LISATA THERAPEUTICS, INC. (LSTA)

Phase 1(5)

Drug	Company
anakinra	Merus N.V. (MRUS)
mt-601 dose 1200 million cells	Marker Therapeutics, Inc. (MRKR)
mt-601 dose 200 million cells	Marker Therapeutics, Inc. (MRKR)
mt-601 dose 400 million cells	Marker Therapeutics, Inc. (MRKR)
mt-601 dose 800 million cells	Marker Therapeutics, Inc. (MRKR)

BioSniper tracks 6 drugs in development for Pancreas Cancer across 3 companies.

There are 13 clinical trials targeting Pancreas Cancer tracked by BioSniper.

The estimated prevalence of Pancreas Cancer is approximately 7.1 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.